In November, Allink Biotherapeutics, Bonovo Biotech and Over 10 Other Chinese Innovative Biotechs Secured Over RMB 100 Million in Financing

　　【Pharmaceuticals Network Industry DynamicsAccording to the review, in November, at least 20 innovative pharmaceutical companies announced the completion of a new round of financing. Among them, 11 companies raised more than 100 million yuan, including Allink Biotherapeutics, BRL Medicine, Worg, and LeadBio Therapeutics.
 

Allink Biotherapeutics Announces Completion of $42 Million Series A Financing. The funds raised will accelerate Allink Biotherapeutics' global expansion, including advancing Phase I clinical trials for its core pipelines ALK201 and ALK202 in Australia, the United States, and China. The company will also actively expand its R&D pipeline in oncology and immunology, continuously optimize its self-developed bispecific antibody and ADC technology platforms, and establish itself as a biotech company with global influence.
 

Data shows that Allink Biotherapeutics is committed to developing a new generation of bispecific antibodies and ADC therapies, providing better treatment options for patients with cancer and immune diseases.
 

BRL Medicine Announces Completion of Nearly 200 Million RMB B+ Round Financing. After securing this round of financing, BRL Medicine will comprehensively advance the clinical transformation and market launch process of its multi-pipeline products, accelerate the global R&D layout of its product pipeline, bringing hope to patients with genetic diseases, malignant tumors, and autoimmune diseases worldwide.
 

Data shows that BRL Medicine focuses on gene and cell therapy. Currently, four projects have been approved for IND and have officially entered the registration clinical trial stage, while several other projects are in the IND application stage.
 

Worg Announces Completion of D-round Financing Worth Hundreds of Millions; This Investment Will Accelerate Worg's New Drug Development Process, Promote the Transformation of Innovative Technologies, and Further Strengthen Its Competitive Position in the Biopharmaceutical Field.
 

Data shows that Worg is committed to developing a new generation of specific immunotherapies for allergic and autoimmune diseases. The company has dozens of commercialized products. It continuously develops two new technology platforms: PCFiT™ (recombinant peptide carrier fusion protein) and Apitope® (tolerogenic peptides), and rapidly builds a pipeline for the research and development of allergy and autoimmune disease indications based on these new technology platforms. Several pipelines, including grass pollen allergy and Graves' disease, have entered phase II and phase III clinical trials in different countries worldwide.
 

LingTai Bio Announces Successful Completion of Over 100 Million Yuan in Series A Financing. The funds raised will mainly be used to accelerate the Phase I and subsequent clinical studies of the company's leading pipeline, IRAK4 degrader LT-002, preclinical development of other autoimmune and oncology pipelines, as well as the establishment of LingTai Shaoxing Research and Development Center and the expansion of the R&D team.
 

Data shows that Leadthera Bio is a biopharmaceutical company dedicated to the research and development of small-molecule innovative drugs. The company mainly focuses on targeted protein degradation (TPD) drug technology, concentrating on disease areas such as autoimmune disorders and cancer.
 

Tongrui Biologics Announces Over $100 Million Series A+ Financing to Further Enhance Core Technology Platforms like Targeted Precursor Discovery, Upgrade High-Throughput Screening for Innovative RDC Drugs, and Accelerate Multiple International R&D Pipelines, Especially the Clinical Development of Alpha Nuclide RDC Drugs, to Bring More Effective Treatment Options to Patients Worldwide.
 

Impa Therapeutics Completes $250 Million D++ Financing Round; Proceeds to Support Commercialization of Core Product Senaparib and Global Clinical Development of Multiple Compounds
 

Lemang Bio announces the successful completion of the first close of its over 100-million-yuan Series A financing round. The proceeds from this round will mainly be used for the IND application of its ultra-low-dose metabolism-enhanced CAR-T cell therapy, the R&D of automated production processes, and accelerating the clinical translation of metabolism-enhanced solid tumor cell therapies.
 

Kanglin Biotech Announces Successful Completion of 150 Million Yuan Series A Financing. This round of financing will accelerate the development of the company's various research pipelines. One of its core products, KL003 Cell Injection (for treating transfusion-dependent β-thalassemia), received clinical trial approval from the China National Medical Products Administration in January 2024 and has begun clinical trials.
 

Zhongsheng溯源 announced the completion of the first close of its RMB 150 million Series B financing. The proceeds from this round will mainly be used to accelerate the clinical development of multiple pipelines in the iPSC cell therapy field by Zhongsheng溯源, as well as the subsequent commercialization of its products, promoting the development of the cell therapy field.
 

Riprecure Announces Completion of Over 100 Million Yuan in Series A Financing; Funds Will Be Used to Accelerate the Company’s R&D Pipeline and Clinical Trial Progress, Further Advancing the Scalable Development and Industrialization of Innovative Cell Therapy Drugs.
 

Ningdan New Drug Announces Completion of CNY Hundreds of Millions in Series C Financing; Proceeds to Accelerate Core Pipeline Development and Market Launch, Independent Innovation Platform Construction, and Global Expansion. The company is an innovative firm focused on the research and industrialization of new drugs for central nervous system (CNS) diseases.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.